Amgen Inc.

293.57
0.03 (0.01%)
At close: Feb 10, 2025, 11:55 AM
undefined%
Bid 293.39
Market Cap 157.80B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 7.57
PE Ratio (ttm) 38.78
Forward PE n/a
Analyst Hold
Ask 295
Volume 742,284
Avg. Volume (20D) 3,931,520
Open 295.93
Previous Close 293.54
Day's Range 290.71 - 296.88
52-Week Range 253.30 - 346.85
Beta undefined

About AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopaus...

Sector Healthcare
IPO Date Jun 17, 1983
Employees 26,700
Stock Exchange NASDAQ
Ticker Symbol AMGN

Analyst Forecast

According to 22 analyst ratings, the average rating for AMGN stock is "Hold." The 12-month stock price forecast is $324, which is an increase of 10.37% from the latest price.

Buy 45.45%
Hold 40.91%
Sell 9.09%
Stock Forecasts

Next Earnings Release

Amgen Inc. is scheduled to release its earnings on May 1, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
+6.5%
Amgen shares are trading higher after the company ... Unlock content with Pro Subscription
6 days ago
+0.05%
Amgen shares are trading lower. The company reported Q4 financial results.